Entity
  • HAYA Therapeutics

    Created in 2019
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    9,319
  • Activities

  • Technologies

  • Entity types

  • Location

    Lausanne, Switzerland

    Lausanne

    Switzerland

  • Employees

    Scale: 11-50

    Estimated: 51

  • Engaged corporates

    3
    2 0
  • Added in Motherbase

    2 months, 3 weeks ago
Description
  • Value proposition

    Inspired to Transform, The Genome Informs - RNA-Guided Therapeutics to Target Disease Causing Cell-States

    HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

    lncRNA, genomic medicines, and fibrosis

  • HAYA Therapeutics | Precision Medicines Targeting the Dark Genome

    We are leveraging the power of the dark genome to develop precise and potent RNA therapies for disease driving cell-state reprogramming.

  • https://www.hayatx.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Innovaud
Innovaud
International Trade and Development
Innovaud
International Trade and Development
Other

3 Jun 2024


MassChallenge
MassChallenge
Startup accelerator & VC, Venture Capital and Private Equity Principals
MassChallenge
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

17 Nov 2023


Bayer
Bayer
Chemistry, Pharmaceutical, Chemical Manufacturing
Bayer
Chemistry, Pharmaceutical, Chemical Manufacturing
Other

15 Sep 2024


Similar entities
Loading...
Loading...
Social network dynamics